Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Alcon Inc | Florida Eye Specialists
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2025
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Alcon Inc | Florida Eye Specialists
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Sengi
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2024
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Sengi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alcon Inc
Deal Size : $930.0 million
Deal Type : Acquisition
Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...
Product Name : Rocklatan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 22, 2022
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alcon Inc
Deal Size : $930.0 million
Deal Type : Acquisition
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alcon Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye di...
Product Name : Rocklatan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 22, 2022
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alcon Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alcon Inc
Deal Size : $930.0 million
Deal Type : Acquisition
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...
Product Name : Rocklatan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 22, 2022
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alcon Inc
Deal Size : $930.0 million
Deal Type : Acquisition
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rocklatan (netarsudil and latanoprost), indicated for reduction of elevated IOP in patients with glaucoma or ocular hypertension, demonstrated consistent IOP reduction of ~9.5 mmHg and an average IOP reduction of 37% from baseline in European Phase 3B cl...
Product Name : Rhopressa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate,Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THC-VHS-NEC (SBI-100) + Rhopressa® (netarsudil) a Rho-Kinase Inhibitor combination , Produces Superior IOP Lowering Activity.THCVHS a synthetic molecule, developed to treat glaucoma.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate,Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate,Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies
Details : THCVHS enables enhanced local delivery of the drug into the eye, provides significant lowering of intraocular pressure, minimal systemic exposure, and potential for neuroprotection.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 08, 2021
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate,Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Santen Pharmaceutical
Deal Size : $168.0 million
Deal Type : Expanded Collaboration
Details : Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rho...
Product Name : Rhopressa
Product Type : Other Small Molecule
Upfront Cash : $88.0 million
July 12, 2021
Lead Product(s) : Netarsudil
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Santen Pharmaceutical
Deal Size : $168.0 million
Deal Type : Expanded Collaboration